Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer

(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect. It said that as both a senior management consultant and investment banker, Dhankhar has advised CEOs and boards at some of the world's leading healthcare companies, helping deliver "substantial shareholder value".

His experience includes 25 years with McKinsey & Company where he was a senior partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D.

Following that, Dhankhar served as a managing director in the financial advisory healthcare group of Lazard, where he was the Global Head of Medical Technology, Diagnostics and Tools.

More recently, he founded and led Bluish Capital, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets.

Chief executive Deepak Nath said: "Ajay's unique blend of scientific rigor, strategic insight, business development, integrations, and operational excellence, combined with his entrepreneurial leadership style, makes him exceptionally well-suited to help shape our future. We are pleased to have him join our leadership team at this exciting time for the company."

Share this article

Related Sharecast Articles

Carr's Group enters manufacturing partnership with Vetalis
(Sharecast News) - Carr's Group announced a strategic manufacturing partnership with French animal health company Vétalis on Friday, to develop an enhanced range of Tracesure boluses, with distribution due to begin in autumn 2025.
JPMorgan puts Softcat on 'negative catalyst watch', shares slump
(Sharecast News) - Softcat slumped on Friday as JPMorgan Cazenove placed the shares on 'negative catalyst watch' ahead of FY25 results.
Berenberg lowers target price on Ashtead Technology
(Sharecast News) - Analysts at Berenberg lowered their target price on Ashtead Technology from 800.0p to 700.0p on Friday following a "tough first half".
BP to sell US onshore wind business to LS Power
(Sharecast News) - BP said on Friday that it has agreed to sell its US onshore wind business, BP Wind Energy, to LS Power, a development, investment and operating company focused on the North American power and energy infrastructure sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.